Novo Nordisk Wegovy Pill Shows Significant Weight Loss and Improved Physical Function in Phase 3 Trial
At the European Congress on Obesity 2026 in Istanbul, Novo Nordisk presented compelling new data from its phase 3 OASIS 4 clinical trial, highlighting the long-term efficacy and functional benefits of its oral obesity treatment, the Wegovy pill. The findings suggest that the oral semaglutide 25 mg treatment offers a clinically meaningful option for weight management, providing both significant weight reduction and improvements in physical capabilities.
Breakthrough Results for Early Responders
The new analyses from the OASIS 4 trial emphasize the importance of early weight loss in predicting long-term outcomes. According to Novo Nordisk, participants who were classified as “early responders”—defined as those who lost at least 10% of their body weight by week 16—saw substantial continued progress.
- Week 16: Early responders achieved an average weight loss of 13.2%.
- Week 64: Those same early responders reached an average weight loss of 21.6%.
The study also demonstrated that the treatment was effective even for those who did not meet the early-response benchmark. Participants who did not achieve the 10% weight loss threshold by week 16 still reported an average weight loss of 11.5% by the conclusion of the study.
Improving Mobility and Physical Function
Beyond weight reduction, the OASIS 4 analysis revealed significant improvements in the quality of life related to physical movement. For participants who initially presented with poor physical function, the Wegovy pill provided a notable boost to their daily capabilities.
The data showed that nearly eight in 10 participants with poor physical function experienced clinically meaningful improvements in function scores while taking the Wegovy pill. This stands in stark contrast to the placebo group, where only 42.9% of participants saw similar improvements. These function scores specifically measured physical capabilities, including range of motion and stamina.
Comparison and Tolerability
In the competitive landscape of obesity treatments, the Wegovy pill demonstrated advantages in both efficacy and patient adherence. Additional analyses presented at the congress suggested that the Wegovy pill produced greater weight loss and lower discontinuation rates due to gastrointestinal side effects when compared to orforglipron.
Key Takeaways: OASIS 4 Trial Results
- Oral Semaglutide 25 mg: Achieved clinically meaningful weight loss regardless of early response status.
- Long-term Efficacy: Early responders reached an average of 21.6% weight loss by week 64.
- Functional Benefits: Nearly 80% of participants with poor physical function saw meaningful improvements.
- Tolerability: Showed lower discontinuation rates due to gastrointestinal issues compared to orforglipron.
Frequently Asked Questions
What is the difference between the Wegovy injection and the Wegovy pill?
While both utilize semaglutide, the Wegovy pill is an oral semaglutide 25 mg treatment designed for once-daily use, providing a non-injectable alternative for obesity management.
How is “physical function” measured in these trials?
In the OASIS 4 trial, function scores measured physical capabilities such as stamina and range of motion to determine how much the treatment improved a patient’s ability to move and perform daily tasks.
What defines an “early responder” in the OASIS 4 study?
An early responder is a participant who achieved a weight loss of at least 10% of their total body weight by the 16th week of treatment.
As the medical community continues to explore oral alternatives to injectable GLP-1 therapies, the data presented at the European Congress on Obesity 2026 marks a significant step forward in providing diverse, effective, and tolerable options for patients managing obesity.